Biochemistry / Redox Biology Center Seminar — Kenneth Tew
“Drug and Biomarker Development on a Redox Platform”
4:00 pm –
5:00 pm
Beadle Center
Room: N172
1901 Vine St
Lincoln NE 68503
Lincoln NE 68503
Additional Info: BEAD
Contact:
Hannah Kahler, (402) 472-3173, redox2@unl.edu
Kennth Tew, Chairman, Department of Pharmacology, John C. West Chair in Cancer Research, Medical University of South Carolina, will present the seminar “Drug Biomarker Development on a Redox Platform” on Tues. January 22, 2013 at 4:00 PM in N172 Beadle Center.
Dr.Tew’s research employs an essential platform that interrogates redox pathways (with special emphasis on glutathione homeostasis) in drug discovery/development, drug resistance and biomarker identification in cancer. In oncology, there is a critical need to identify new drugs with clinical utility and biomarkers that correlate with drug responses. Recently, research has focused upon specific post-translationally modified, S-glutathionylated proteins that influence cell-signaling pathways and may serve as surrogate plasma biomarkers for oxidative and nitrosative stress. Translational research efforts have resulted in one glutathione S-transferase activated prodrug and two small molecule drugs that are under clinical development.
Dr.Tew’s research employs an essential platform that interrogates redox pathways (with special emphasis on glutathione homeostasis) in drug discovery/development, drug resistance and biomarker identification in cancer. In oncology, there is a critical need to identify new drugs with clinical utility and biomarkers that correlate with drug responses. Recently, research has focused upon specific post-translationally modified, S-glutathionylated proteins that influence cell-signaling pathways and may serve as surrogate plasma biomarkers for oxidative and nitrosative stress. Translational research efforts have resulted in one glutathione S-transferase activated prodrug and two small molecule drugs that are under clinical development.